8-K/A: Turning Point Brands Soars on Q3 2025 Results, Boosts Outlook

Turning Point Brands reported strong third-quarter 2025 financial results, with consolidated net sales up 31.2% and a significant increase in Modern Oral sales, leading to an upward revision of full-year guidance.

Summary

• Consolidated Net Sales for Q3 2025 increased 31.2% year-over-year to $119.0 million.
• Modern Oral Net Sales for Q3 2025 surged 627.6% year-over-year to $36.7 million, representing 30.8% of total Company Net Sales.
• Q3 2025 Adjusted EBITDA was $31.3 million, up 17.2% over the prior year.
• Net Income increased 70.3% to $21.1 million.
• Diluted EPS was $1.13 and Adjusted Diluted EPS was $1.05, compared to $0.68 and $0.91 respectively, in Q3 2024.
• The company raised $97.5 million in net proceeds from an At the Market offering program at an average price of $98.59 per share.
• Full-year 2025 Adjusted EBITDA guidance increased to $115.0 $120.0 million (from $110.0 $114.0 million).
• Full-year 2025 Modern Oral sales guidance increased to $125.0 $130.0 million (from $100.0 $110.0 million).
• Stokers segment net sales increased 80.8% to $74.8 million, driven by strong growth in Modern Oral sales, mid-single-digit growth in MST, and low-single-digit growth in looseleaf.
• Zig-Zag segment net sales decreased 10.5% from the prior year to $44.2 million, primarily due to the wind-down of the Clipper business.
• Total gross debt as of September 30, 2025, was $300.0 million, with net debt at $98.8 million.
• Total liquidity was $267.8 million, comprised of $201.2 million in cash and $66.6 million of availability under an asset-backed revolving credit facility.

Sentiment

Score: 8

Explanation: The company reported strong Q3 results, significantly exceeding expectations, particularly in the high-growth Modern Oral segment. Upward revisions to full-year guidance for both Adjusted EBITDA and Modern Oral sales, coupled with a successful capital raise for growth initiatives, indicate a very positive outlook despite some declines in traditional segments.

Positives

• Consolidated Net Sales increased 31.2% year-over-year to $119.0 million.
• Modern Oral Net Sales grew 627.6% year-over-year to $36.7 million, now comprising 30.8% of total net sales.
• Adjusted EBITDA increased 17.2% to $31.3 million.
• Net Income increased 70.3% to $21.1 million.
• Diluted EPS increased to $1.13 from $0.68 in the prior year.
• Adjusted Diluted EPS increased to $1.05 from $0.91 in the prior year.
• Stokers segment net sales increased 80.8% to $74.8 million, with gross margin up 440 basis points to 60.2%.
• Company increased full-year 2025 Adjusted EBITDA guidance to $115.0 $120.0 million (from $110.0 $114.0 million).
• Company increased full-year 2025 Modern Oral sales guidance to $125.0 $130.0 million (from $100.0 $110.0 million).
• Strong cash position with $201.2 million in cash and $267.8 million in total liquidity.
• Zig-Zag segment gross margin increased 210 basis points from the prior year to 57.5%.

Negatives

• Zig-Zag segment Net Sales decreased 10.5% year-over-year to $44.2 million, primarily due to the previously discussed wind-down of the Clipper business.
• Consolidated selling, general and administrative (SG&A) expenses increased 50.5% year-over-year to $44.5 million, inclusive of increased Modern Oral-related sales and marketing investments and increased outbound freight costs.

Risks

• Forward-looking statements involve inherent risks and uncertainties, as they relate to future events and circumstances that may or may not occur, and are not guarantees of future performance.
• Actual events may differ materially from those expressed or suggested in forward-looking statements.
• New risks and uncertainties emerge periodically, and it is impossible for the company to predict or identify all such events or their potential impact.
• Preliminary estimates are subject to completion of customary quarter-end closing and review procedures and third-party review, meaning reported information in the Form 10-Q may differ materially.
• Costs associated with applications related to FDA premarket tobacco product application (PMTA) for Modern Oral products, which is a resource-intensive process that can take multiple years to complete for existing product lines.

Future Outlook

The company is increasing its full-year 2025 Adjusted EBITDA guidance to $115.0 $120.0 million (from $110.0 $114.0 million) and projected full-year 2025 Modern Oral sales guidance to $125.0 $130.0 million (from $100.0 $110.0 million). It also expects to qualify its first U.S. white pouch production lines in the first half of 2026.

Management Comments

• "Our consolidated third quarter results exceeded expectations."
• "Modern Oral sales were $36.7 million, increasing by 22% versus the prior quarter and 628% over the prior year."
• "In addition, we now expect to qualify our first U.S. white pouch production lines in the first half of 2026."

Industry Context

The strong growth in Modern Oral sales highlights a significant shift in the consumer products industry towards alternative nicotine products, moving away from traditional tobacco. This trend is likely driven by evolving consumer preferences and regulatory pressures on conventional smoking products. The decline in Zig-Zag sales, even with the Clipper wind-down, suggests challenges in traditional smoking accessories, while the robust performance of Stokers (driven by Modern Oral) indicates successful adaptation to market changes. The investment in Modern Oral production lines positions the company to capitalize further on this growing segment.

Legal Proceedings

• Incurred $0.437 million in non-recurring legal expenses in Q3 2025 related to litigation concerning an insurance claim.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and strategic capital deployment for growth. Potential for future share price appreciation.
• Employees: Continued growth in the Modern Oral segment may lead to job creation and stability, particularly with new production lines.
• Customers: Expansion of Modern Oral products and production capacity suggests broader availability and innovation in alternative nicotine products.
• Creditors: Improved financial health and liquidity strengthen the company's ability to meet its debt obligations.

Next Steps

• Qualify first U.S. white pouch production lines in the first half of 2026.
• Amend ATM prospectus supplement and buyback authorization to provide for $200 million of capacity under each program.
• Hold a conference call with the investment community on November 5, 2025, at 8:30 a.m. Eastern.
• File Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Key Dates

Recommendation

The company delivered exceptional Q3 2025 results, significantly surpassing expectations, driven by explosive growth in its Modern Oral segment (up 627.6% year-over-year). This performance led to a substantial increase in full-year guidance for both Adjusted EBITDA and Modern Oral sales, indicating strong momentum and confidence in future growth. The successful capital raise of $97.5 million, earmarked for high-return opportunities in Modern Oral, further strengthens its strategic position. While the Zig-Zag segment saw a decline, it was largely attributed to a planned wind-down, and the underlying business showed sequential improvement. The company's ability to pivot towards high-growth, next-generation products, coupled with robust financial metrics and a healthy liquidity position, makes it a compelling investment. The qualification of new U.S. white pouch production lines in H1 2026 signals continued innovation and market expansion.

Keywords

Turning Point Brands, TPB, Q3 2025, earnings, financial results, Modern Oral, Stokers, Zig-Zag, Adjusted EBITDA, net sales, EPS, tobacco, alternative smoking, consumer products, SEC filing, 8-K/A